In short
Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO15 among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to assess the vaccine's ability to prevent serious E. coli infections and its safety profile.
At a glance
- Vaccine Name
- ExPEC9V (JNJ-78901563)
- Target Population
- Adults aged 60 years and older with a history of urinary tract infections
- Main Objective
- Prevent invasive extraintestinal pathogenic E. coli disease
- Administration
- Intramuscular injection
- Key Components
- ECOO1A, ECOO2, ECOO4, ECOO6A, ECOO15, ECOO16, ECOO18A, ECOO25B, ECOO75
- Trial Phase
- Phase 3
- Primary Endpoints
- Prevention of first IED event caused by ExPEC serotypes; Antibody response to vaccine antigens
- Secondary Endpoints
- Prevention of UTIs, pyelonephritis, and hospitalized IED events; Safety and reactogenicity; Quality of life impact
What is ECOO15?
ECOO15 is one of the active components in a new vaccine called ExPEC9V (also known as JNJ-78901563). This vaccine is being developed to prevent invasive diseases caused by certain types of Escherichia coli bacteria. E. coli is a common bacteria found in the human gut, but some strains can cause serious infections outside the intestines, such as in the urinary tract or bloodstream.
Purpose of ECOO15
ECOO15 is specifically designed to target the O15 serotype of extraintestinal pathogenic E. coli (ExPEC). ExPEC are strains of E. coli that can cause infections outside the intestinal tract. The ExPEC9V vaccine, which includes ECOO15, aims to prevent invasive extraintestinal pathogenic Escherichia coli disease (IED). This can include serious conditions such as: Urinary tract infections (UTIs): Infections in any part of the urinary system Bacteremia: Presence of bacteria in the blood Sepsis: A life-threatening condition caused by the body's response to an infection Pyelonephritis: A serious kidney infection
Target Population
The ExPEC9V vaccine, which includes ECOO15, is being studied in adults aged 60 years and older. This population is particularly targeted because: They have a higher risk of developing invasive E. coli infections They often have a history of urinary tract infections Their immune systems may be less effective at fighting off infections Specifically, the vaccine is being tested in people who have had a urinary tract infection in the past 2 years and have at least one additional risk factor for invasive E. coli disease.
Clinical Trials
ECOO15, as part of the ExPEC9V vaccine, is currently being studied in Phase 3 clinical trials. These are large-scale studies designed to test the effectiveness and safety of the vaccine. Two important trials are: A study comparing ExPEC9V with a high-dose influenza vaccine in adults 65 years and older. A study testing ExPEC9V against a placebo in adults 60 years and older with a history of urinary tract infections. These trials aim to determine how well the vaccine prevents invasive E. coli disease and how safe it is for use in older adults.
Potential Benefits
If successful, the ExPEC9V vaccine containing ECOO15 could provide several benefits: Prevention of invasive E. coli infections, including serious UTIs and bloodstream infections Reduction in hospitalizations related to E. coli infections Decreased need for antibiotics, potentially helping to combat antibiotic resistance Improved quality of life for older adults who are prone to recurrent UTIs
Safety and Side Effects
As with any vaccine, safety is a crucial consideration. The clinical trials are carefully monitoring for any side effects. Common side effects of vaccines can include: Pain, redness, or swelling at the injection site Mild fever Fatigue Headache The trials are specifically looking at both solicited (expected) and unsolicited (unexpected) adverse events, as well as any serious adverse events that may occur. This thorough monitoring helps ensure the vaccine's safety before it can be approved for general use.
Conclusion
ECOO15, as a component of the ExPEC9V vaccine, represents a promising approach to preventing serious E. coli infections in older adults. While still in the testing phase, this vaccine could potentially provide significant health benefits to a vulnerable population. As always, it's important to discuss any new medical treatments or vaccines with your healthcare provider to determine if they are appropriate for your individual health needs.